The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology

Anti-Cancer Drugs

Volumn 23, Issue 4, 2012, Pages 347-354

  Kampen, Kim R ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

angiogenesis; cancer prognosis; cancer therapy; kinase insert domain receptor; vascular endothelial growth factor receptor 2

Indexed keywords

CABOZANTINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEPTIN; RAMUCIRUMAB; SEMAXANIB; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL NUCLEUS; CENTRAL NERVOUS SYSTEM TUMOR; COLORECTAL CANCER; CYTOPLASM; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMANGIOBLASTOMA; HUMAN; HYPOXIA; KIDNEY CANCER; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; MULTIPLE MYELOMA; MYELOMA; NEUROENDOCRINE TUMOR; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUALITY OF LIFE; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOLID TUMOR; THYROID MEDULLARY CARCINOMA; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CANCER; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84858284474     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835004ac     Document Type: Review

References (71)

1. Gampel A, Moss L, Jones MC, Brunton V, Norman JC, Mellor H. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood 2006; 108:2624-2631.
2. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61:1786-1790. (Pubitemid 32691984)
3. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-2049. (Pubitemid 351656458)
4. Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007; 13:5544s-5548s. (Pubitemid 47510385)
5. Kampen KR. Membrane proteins: the key players of a cancer cell. J Membr Biol 2011; 242:69-74.
6. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006; 175:1245-1252.
7. Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z, et al. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol 2011; 64:343-348.
8. SpannuthWA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009; 124:1045-1053.
9. Loganathan S, Kanteti R, Siddiqui SS, El-Hashani E, Tretiakova M, Vigneswaran H, et al. Role of protein kinase C beta and vascular endothelial growth factor receptor in malignant pleural mesothelioma: therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinol 2011; 10:4.
10. Giatromanolaki A, Koukourakis MI, Sivridis E, Chlouverakis G, Vourvouhaki E, Turley H, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007; 37:878-886. (Pubitemid 350029203)
11. Giatromanolaki A, Bai M, Margaritis D, Bourantas KL, Koukourakis MI, Sivridis E, et al. Hypoxia and activated VEGF/receptor pathway in multiple myeloma. Anticancer Res 2010; 30:2831-2836.
12. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95:309-313. (Pubitemid 30017257)
13. Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16:1302-1310.
14. Giatromanolaki A, Koukourakis MI, Turley H, Sivridis E, Harris AL, Gatter KC. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol 2006; 19:701-707.
15. Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ, et al. Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50:1647-1660.
16. Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol 2010; 148:235-244.
17. Rodriguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010; 17:7-16.
18. Taylor M, Rossler J, Geoerger B, Laplanche A, Hartmann O, Vassal G, et al. High levels of circulating VEGFR2 + Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 2009; 15:4561-4571.
19. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 2011; 71:5512-5521.
20. Nobusawa S, Stawski R, Kim YH, Nakazato Y, Ohgaki H. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Neuropathology 2011. doi: 10.1111/j.1440-1789.2011.01204.
21. Ozdemir F, Akdogan R, Aydin F, Reis A, Kavgaci H, Gul S, et al. The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res 2006; 25:83-88.
22. Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 2010; 1806:108-121.
23. Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005; 8:197-204. (Pubitemid 41759144)
24. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004; 103:3883-3889. (Pubitemid 38596309)
25. Adham SA, Coomber BL. Glucose is a key regulator of VEGFR2/KDR in human epithelial ovarian carcinoma cells. Biochem Biophys Res Commun 2009; 390:130-135.
26. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, et al. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 2008; 7:2553-2561.
27. Thorat MA, Badve S. Nuclear expression of vascular endothelial growth factor receptor-2 in lobular breast cancers: confirmation of serendipitious observation. Journal of Clinical Oncology, ASCO 2008 Breast Cancer meeting, abstract # 127. Available at http://www.asco.org/ascov2/ Meetings/Abstracts? &vmview =abst-detail-view&confID= 58 &abstractID= 40379.
28. Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 2010; 17:1862-1869.
29. Taba M, Nakayama T, Naito S, Mihara Y, Naruke Y, Miura S, et al. Differential expression of vascular endothelial growth factor (VEGF) and VEGF receptors in the sequence of hyperplastic polyp, serated adenoma and adenocarcinoma of the colorectum. Acta Med Nagaski 2008; 53:85-88.
30. Pisacane AM, Risio M. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res 2005; 15:39-43. (Pubitemid 40354472)
31. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94:1647-1654. (Pubitemid 26320271)
32. Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, Yin L, et al. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 2008; 7:1551-1561.
33. Gaumann AK, Schermutzki G, Mentzel T, Kirkpatrick CJ, Kriegsmann JB, Konerding MA. Microvessel density and VEGF/VEGF receptor status and their role in sarcomas of the pulmonary artery. Oncol Rep 2008; 19:309-318. (Pubitemid 351176089)
34. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 2008; 3:e1652.
35. Bougatef F, Menashi S, Khayati F, Naimi B, Porcher R, Podgorniak MP, et al. EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. PLoS One 2010; 5:e12265.
36. Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 2000; 60:888-891. (Pubitemid 30129521)
37. Ji W, Yang J,Wang D, Cao L, Tan W, Qian H, et al. hSULF-1 gene exhitibs anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. Plos One 2011; 6:e23274.
38. Narita K, Staub J, Chien J, Meyer C, Bauer M, Friedl A, et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 2006; 66:6025-6032.
39. Khurana A, Liu P, Mellone P, Lorenzon L, Vincenzi B, Datta K, et al. HSulf-1 mmodulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res 2011; 71:2152-2161.
40. Kim MO, Kim SH, Oi N, Lee MH, Yu DH. Embryonic stem-cellpreconditioned microenvironment induces loss of cancer cell properties in human melanoma cells. Pigment Cell Melanoma Res 2011. doi: 10.1111/ j.1755-148X.2011.00891.
41. Jakobsson L, Franco CA, Bentley K, Collins RT, Ponsioen B, Aspalter IM, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 2010; 12:943-953.
42. Huang X, Raskovalova T, Lokshin A, Krasinskas A, Devlin J,Watkins S, et al. Combined antiangiogenic and immune therapy of prostate cancer. Angiogenesis 2005; 8:13-23. (Pubitemid 41223835)
43. Zhang H, Li Y, Li H, Bassi R, Jimenez X,Witte L, et al. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk Lymphoma 2004; 45:1887-1897. (Pubitemid 38997158)
44. Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003; 17:604-611. (Pubitemid 36395655)
45. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002; 5:35-44. (Pubitemid 36076921)
46. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059-1066.
47. Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010; 28: 4762-4768.
48. Kieran MW, Supko JG,Wallace D, Fruscio R, Poussaint TY, Phillips P, et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 2009; 52:169-176.
49. Fury MG, Zahalsky A,Wong R, Venkatraman E, Lis E, Hann L, et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007; 25:165-172. (Pubitemid 46020876)
50. Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E,Weiss GR, et al. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol 2007; 59:165-174. (Pubitemid 44885146)
51. Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, et al. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am J Clin Oncol 2006; 29:109-115. (Pubitemid 44270946)
52. Hoff PM,Wolff RA, Bogaard K,Waldrum S, Abbruzzese JL. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol 2006; 36:100-103.
53. Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 2005; 55:295-300. (Pubitemid 40142895)
54. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res 2004; 10:5732-5740. (Pubitemid 39180949)
55. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004; 10:4048-4054. (Pubitemid 38812480)
56. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, et al. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004; 10:3365-3370. (Pubitemid 38685441)
57. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102:2763-2767. (Pubitemid 37248845)
58. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10:88-95. (Pubitemid 38114166)
59. Yau T, Chan P, Pang R, Ng K, Fan ST, Poon RT. Phase 1-2 trial of PTK787/ ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 2010; 116:5022-5029.
60. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29:1997-2003.
61. Cook N, Basu B, Biswas S, Kareclas P, Mann C, Palmer C, et al. A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer 2010; 46:2671-2673.
62. Joensuu H, De BF, Grignagni G, De PT, Spitalieri G, Coco P, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011; 104:1686-1690.
63. Vij R, Ansstas G, Mosley JC, Bryant G, Hassan A, Amador-Ortiz C, et al. Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2010; 51:1577-1579.
64. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12:443-450. (Pubitemid 46698722)
65. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010; 46:348-354.
66. Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2006; 20:952-957. (Pubitemid 43797284)
67. Mackey J, Gelmon K, Martin M, McCarthy N, Pinter T, Rupin M, et al. TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer 2009; 9:258-261.
68. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-979. (Pubitemid 41635382)
69. Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011; 102: 1374-1380.
70. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
71. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, et al. Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic 2006; 7:1270-1282. (Pubitemid 44204001)